Irinotecan (CPT-11): Pharmacology and clinical applications

Critical Reviews in Oncology/Hematology

Volumn 24, Issue 1, 1996, Pages 3-26

  Masuda, Noriyuki ^a   Kudoh, Shinzoh ^b   Fukuoka, Masahiro ^c  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DNA TOPOISOMERASE; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINDESINE;

ALOPECIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG RESISTANCE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LEUKEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH; REVIEW; SOLID TUMOR; UTERINE CERVIX CANCER; VOMITING;

EID: 0030249075     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00201-6     Document Type: Review

References (114)

1. [1] Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890, 1966.
2. [2] Drewinko B, Freireich E, Gottlieb J. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34:747-750, 1974.
3. [3] Gallo R, Whang-Peng J, Adamson R. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46:789-795, 1971.
4. [4] Creaven P, Allen L, Muggia F. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56:573-578, 1972.
5. [5] Gottlieb J, Guarino A, Call J, Oliverio V, Block J. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970.
6. [6] Gottlieb J, Luce J. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105, 1972.
7. [7] Moertel C, Schutt A, Reitemeier R, Haln R. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972.
8. [8] Muggia F, Creaven P, Hansen H, Cohen M, Selawry O. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515-521, 1972.
9. [9] Creasey WA, Richards M, Tsou K. Action of (S)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice. Cancer Treat Rep 67:179-182, 1983.
10. [10] Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors. J Pharmacobio-Dyn 10:148-151, 1987.
11. [11] Nagata H, Kaneda N, Furuta T, et al. Action of 7-ethylcamptothecin on tumor cells and its disposition in mice. Cancer Treat Rep 71:341-348, 1987.
12. [12] Yang J, Han J, Xu B. Distribution and excretion of 10-hydroxycamptothecin and its influence on the immune response. Acta Pharmacol Sin 1:44-48, 1980.
13. [13] Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987.
14. [14] Slichenmyer W, Von Hoff D. New natural products in cancer chemotherapy. J Clin Pharmacol 30:770-788, 1990.
15. [15] Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74, 1988.
16. [16] Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobio-Dyn 14:341-349, 1991.
17. [17] Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191, 1991.
18. [18] Andoh T, Ishii K, Suzuki Y, et al. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565-569, 1987.
19. [19] Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985.
20. [20] Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990.
21. [21] Tsuda H, Takatsuki K, Ohno R, et al. A late phase II trial of a potent topoisomerase I inhibitor, CPT-11, in malignant lymphoma. Proc Am Soc Clin Oncol 11:316, 1992 (Abstr).
22. [22] Negoro S, Fukuoka M, Niitani H, Taguchi T. Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:241, 1991 (Abstr).
23. [23] Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
24. [24] Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992.
25. [25] Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11. a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993.
26. [26] Takeuchi S, Takamizawa H, Takeda Y, et al. An early phase II study of CPT-11 for gynecologic cancers. Gan To Kagaku Ryoho 18:579-584, 1991 (in Japanese).
27. [27] Tacheuchi S, Dobashi K, Fujimoto S, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Gan To Kagaku Ryoho 18:1681-1689, 1991 (in Japanese).
28. [28] Venditti JM, Abbott BJ. Studies on oncolytic agents from natural sources. Correlation of activity against animal tumors and clinical effectiveness. Lloydia 30:332-348, 1967.
29. [29] Venditti JM. Treatment schedule dependency of experimentally active antileukemic (L1210) drugs. Cancer Chemother Rep 2:35-59, 1971.
30. [30] Wani MC, Ronman PE, Lindley JT, Wall ME. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 23:554-560, 1980.
31. [31] Sawada S, Okajima S, Aiyama R, et al. Synthesis and antitumor activity of 20 (S)-camptothecin derivatives: carvamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull 39:1446-1454, 1991.
32. [32] Furuta T, Yokokura T, Mutai M. Antitumor activity of CPT-11 against rat Walker carcinoma. Gan To Kagaku Ryoho 15:2757-2760, 1988 (in Japanese).
33. [33] Bissery MC, Mathieu-Boue A, Lavelle F. Experimental antitumor activity of CPT-11 in vitro and in vivo. In: Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1992, 82 (Abstr).
34. [34] Matsuzaki T, Yokokura T, Mutai M, Tsuruo T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988.
35. [35] Furuta T, Yokokura T. Effect of administration schedule on the antitumor activity of CPT-11, a camptothecin derivative. Gan To Kagaku Ryoho 17:121-130, 1990 (in Japanese).
36. [36] Kudoh S, Takada M, Masuda N, et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993.
37. [37] Wang Y, Inoue K, Shibata H, Itoh Y, Chen SC, Ogawa M. Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay. Gan To Kagaku Ryoho 14:1264-1267, 1987 (in Japanese).
38. [38] Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720, 1990.
39. [39] Shimada Y, Rothenberg M, Hilsenbeck SG et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anti-Cancer Drugs 5:202-206, 1994.
40. [40] Kaneda N, Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725, 1990.
41. [41] Kono A, Hara Y. Conversion of CPT-11 into SN-38 in human. Gan To Kagaku Ryoho 18:2175-2178, 1991.
42. [42] Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375, 1989.
43. [43] D'Arpa P, Liu LF. Topoisomerase-targeting antitumor drugs. Biochem Biophys Acta 989:163-177, 1989.
44. [44] Gellert M. DNA topoisomerases. Annu Rev Biochem 50:879-910, 1981.
45. [45] Wang JC. DNA topoisomerases. Annu Rev Biochem 54:665-697, 1985.
46. [46] Schneider E, Hsiang YH, Liu L. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149-183, 1990.
47. [47] Liu LF, Miller KG. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from Hela cell nuclei. Proc Natl Acad Sci USA 78:3487-3491, 1981.
48. [48] Liu L, Fraser T, Olin E, Bhuyan B. Action of camptothecin on mammalian cells in culture. Cancer Res 32:2643-2650, 1972.
49. [49] Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991.
50. [50] Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50:5919-5924, 1990.
51. [51] Gupta RS, Gupta R, Eng B, et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48:6404-6410, 1988.
52. [52] Tamura H, Kohchi C, Yamada R, et al. Molecular cloning of a CDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucl Acids Res 19:69-75, 1991.
53. [53] Taguchi T, Wakui A, Hasegawa K, et al. Phase I clinical study of CPT-11. Gan To Kagaku Ryoho 17:115-120, 1990 (in Japanese).
54. [54] Abigerges D, Chabot GG, Armand J-P, et al. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995.
55. [55] Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994.
56. [56] Catimel G, Chabot GG, Gustalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995.
57. [57] Nagata H. Flow cytometric analysis of the effect of an antitumor alkaloid, camptothecin, on cell cycle progression of KB cells. J Aichi Med Univ Assoc 15:683-699, 1987.
58. [58] Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991.
59. [59] Rothenberg M, Kuhn J, Burris III H, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993.
60. [60] Gandia D, Abigerges D, Armand J, et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11:196-197, 1993.
61. [61] de Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994.
62. [62] Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972-974, 1991.
63. [63] Abigerges D, Armand J-P, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994.
64. [64] Nakai H, Fukuoka M, Furuse K, et al. An early phase II study of CPT-11 for primary lung cancer. Gan To Kagaku Ryoho 18:607-612, 1991 (in Japanese).
65. [65] Masuda N, Fukuoka M, Furuse K. CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. Oncology 49:19-24 (Suppl), 1992.
66. [66] Bugat R, Sue E, Rougier Ph, et al. CPT-11 (Irinotecan) as second line therapy in advanced colorectal cancer (CRC): preliminary results of a multicentric phase II study. Proc Am Soc Clin Oncol 13:200, 1994 (Abstr).
67. [67] Rougier Ph, Culine S, Bugat R, et al. Multicentric phase II study of first line CPT-11 (Irinotecan) in advanced colorectal cancer (CRC): preliminary results. Proc Am Soc Clin Oncol 13:200, 1994 (Abstr).
68. [68] Bugat R, Rougier P, Douilland JY, et al. Efficacy of Irinotecan HCl (CPT-11) in patients with metastatic colorectal cancer after progression while receiving a 5FU-based chemotherapy. Proc Am Soc Clin Oncol 14:222, 1995 (Abstr).
69. [69] Conti JA, Kemeny N, Saltz L, et al. Irinotecan (CPT-11) is active agent in untreated patients (pts) with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 13:195, 1994 (Abstr).
70. [70] Pitot HC, Wender D, O'Connell MJ, et al. A phase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 13:197, 1994 (Abstr).
71. [71] Rothenberg ML, Eckardt JR, Burris III HA, et al. Irinotecan (CPT-11) as second-line therapy for pts with 5-FU-refractory colorectal cancer. Proc Am Soc Clin Oncol 13:198, 1994 (Abstr).
72. [72] Takeuchi S, Noda K, Yakushiji M, CPT-11 Study Group on Gynecologic malignancy. Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma (CC). Proc Am Soc Clin Oncol 11:224, 1992 (Abstr).
73. [73] Kambe M, Wakui A, Nakao I. A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 12:198, 1993 (Abstr).
74. [74] Sakata Y, Wakui A, Nakao I. A late phase II study of irinotecan (CPT-11 ) in advanced pancreatic cancer. Proc Am Soc Clin Oncol 12:211, 1993 (Abstr).
75. [75] Bonneterre J, Pion J, Adenis A, et al. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. Proc Am Soc Clin Oncol 12:94, 1993 (Abstr).
76. [76] Takada M, Fukuoka M, Kudoh S, Masuda N, Nakagawa K, Kishimoto S. Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Proc Am Assoc Cancer Res 33:226, 1992 (Abstr).
77. [77] Noda K, Takeuchi S, Yakushiji M, et al. Late phase II study of CPT-11, new camptothecin derivative, in cervical and ovarian carcinoma. Proc World Congr Gynecol Obstet 13:279, 1991 (Abstr).
78. [78] Zwelling L, Kohn K. Mechanism of action of cisdichlorodiammineplatinum (II). Cancer Treat Rep 63:1439-1444, 1979.
79. [79] Gottlieb J, Drewinko B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621-628, 1975.
80. [80] Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992.
81. [81] Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993.
82. [82] Kennedy P, Presant CA, Blayney D, Wiseman C, King M, Gala K. Sandostatin (S) therapy for chemotherapy (CT) and radiotherapy (RT) related diarrhea (D). Proc Am Soc Clin Oncol 9:324, 1990 (Abstr).
83. [83] Petrelli N, Rodriguez-Bigas M, Creaven P, Rustum Y. Efficacy of somatostatin analogue (SMS), sandostatin, for treatment of chemotherapy induced diarrhea in colorectal cancer. Proc Am Soc Clin Oncol 11:170, 1992 (Abstr).
84. [84] Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988.
85. [85] Morstyn G, Souza LM, Keech J, Sheridan W. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1(8587):667-672, 1988.
86. [86] Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991.
87. [87] Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12:90-96, 1994.
88. [88] Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 69:585-594, 1980.
89. [89] DeVita VT. Dose-response is alive and well. J Clin Oncol 4:1157-1159, 1986.
90. [90] Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986.
91. [91] Levin L, Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol 14:12-19 (suppl 4), 1987.
92. [92] DeVita VT, Hubbard SM, Longo DL. The chemotherapy of lymphomas: looking back, moving forward. The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47:5810-5824, 1987.
93. [93] Devita VT, Hubbard SM, Longo DL. Treatment of Hodgkin's disease. J Natl Cancer Inst Monogr 10:19-28, 1990.
94. [94] Shinkai T, Arioka H, Kunikane H, et al. A phase I study of CPT-11 and cisplatin in combination with fixed dose of vindesine in metaslatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:328, 1993 (Abstr).
95. [95] Beck WT. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases. J Natl Cancer Inst 81:1683-1685, 1989.
96. [96] Tan KB, Mattern MR, Eng W-K, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732-1735, 1989.
97. [97] Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50:7962-7965, 1990.
98. [98] Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer 50:604-610, 1992.
99. [99] Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809-813, 1987.
100. [100] Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871-877, 1990.
101. [101] Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12:1833-1841, 1994.
102. [102] Taudou G, Portemer C, Jaxel C, Duguet M. Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons. Biochem Pharmacol 45:331-337, 1993.
103. [103] D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924, 1990.
104. [104] Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51:1129-1136, 1991.
105. [105] Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-766, 1992.
106. [106] Bertrand R, O'Connor PM, Kerrigan D, Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743-748, 1992.
107. [107] Karato A, Sasaki Y, Shinkai T, et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 11:2030-2035, 1993.
108. [108] Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 12:196, 1993 (Abstr).
109. [109] Nakagawa K, Fukuoka M, Niitani H. Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 12:332, 1993 (Abstr).
110. [110] Sasaki Y, Sudo K, Yoshida Y, et al. Pharmacokinetic variability of active lactones of CPT-11 and SN-38. Proc Jpn Cancer Assoc 52:630, 1993 (Abstr).
111. [111] Chabot GG, Abigerges D, Gandia D, et al. Pharmacokinetic-pharmacodynamic relationships in patients administered with CPT-11, a new camptothecin analogue. Proc Am Assoc Cancer Res 33:266, 1992 (Abstr).
112. [112] Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159-1169, 1991.
113. [113] Eng W-K, McCabe FL, Tan KB, et al. Development of a stable camptothecin-resistant subline of P 388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471-480, 1990.
114. [114] Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86:1096-1098, 1994.